Literature DB >> 19939861

Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment.

Kagan Gürkan1, Ayhan Bilgiç, Serhat Türkoglu, Birim G Kiliç, Ayla Aysev, Runa Uslu.   

Abstract

The current study was designed to investigate the changes that occur in depression, anxiety, obsessive-compulsive symptoms and health-related quality of life during methylphenidate (MPH) treatment in children with attention-deficit hyperactivity disorder (ADHD). Forty-five treatment naive children with ADHD, aged 8-14, were assessed based on self, parent and teacher reports at the baseline and at the end of the first and third month of MPH treatment regarding changes in inattention, hyperactivity, impulsivity, depression, anxiety and obsessive-compulsive symptoms. Changes in the quality of life were also noted. Repeated measures of analysis of variance (ANOVA) tests with Bonferroni corrections were conducted in order to evaluate the data. Symptoms of inattention, hyperactivity and impulsivity were significantly reduced (p < 0.017) following a three-month MPH treatment. There were significant decreases in depression (p = 0.004), trait anxiety (p = 0.000) and checking compulsion symptom scores (p = 0.001). Moreover, parents reported significant improvements in psychosocial (p = 0.001) and total scores (p = 0.009) of quality of life, despite no change in physical health scores (p > 0.05). Children's ratings of quality of life measures showed no significant changes in physical health and psychosocial scores (p > 0.05), while total scores significantly improved (p = 0.001) after the treatment. Over a three-month MPH treatment, depression, trait anxiety and checking compulsion symptoms decreased and quality of life seemed to improve along with those of inattention, hyperactivity and impulsivity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19939861     DOI: 10.1177/0269881109348172

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  13 in total

1.  [Effect of baicalin on behavioral characteristics of rats with attention deficit hyperactivity disorder].

Authors:  Rong-Yi Zhou; Xin-Min Han; Jiao-Jiao Wang; Hai-Xia Yuan; Ji-Chao Sun; Yue You; Yu-Chen Song
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-08

2.  Peer dislike and victimisation in pathways from ADHD symptoms to depression.

Authors:  Arunima Roy; Catharina A Hartman; René Veenstra; Albertine J Oldehinkel
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-10-28       Impact factor: 4.785

3.  Pre-Existing Comorbid Emotional Symptoms Moderate Short-Term Methylphenidate Adverse Effects in a Randomized Trial of Children with Attention-Deficit/Hyperactivity Disorder.

Authors:  Tanya E Froehlich; William B Brinkman; James L Peugh; Alexandra N Piedra; Daniel J Vitucci; Jeffery N Epstein
Journal:  J Child Adolesc Psychopharmacol       Date:  2019-12-16       Impact factor: 2.576

Review 4.  Pharmacological management of treatment-resistant obsessive-compulsive disorder.

Authors:  Anat Abudy; Alzbeta Juven-Wetzler; Joseph Zohar
Journal:  CNS Drugs       Date:  2011-07       Impact factor: 5.749

5.  Case Report: Treatment of a Comorbid Attention Deficit Hyperactivity Disorder and Obsessive-Compulsive Disorder With Psychostimulants.

Authors:  Ezgi Dogan-Sander; Maria Strauß
Journal:  Front Psychiatry       Date:  2021-05-12       Impact factor: 4.157

6.  A lack of functional NK1 receptors explains most, but not all, abnormal behaviours of NK1R-/- mice(1).

Authors:  A J Porter; K Pillidge; Y C Tsai; J A Dudley; S P Hunt; S N Peirson; L A Brown; S C Stanford
Journal:  Genes Brain Behav       Date:  2015-02-01       Impact factor: 3.449

Review 7.  Methylphenidate for attention problems in epilepsy patients: Safety and efficacy.

Authors:  Beth A Leeman-Markowski; Jesse Adams; Samantha P Martin; Orrin Devinsky; Kimford J Meador
Journal:  Epilepsy Behav       Date:  2020-12-24       Impact factor: 2.937

8.  Differences in the performance of NK1R-/- ('knockout') and wildtype mice in the 5‑Choice Continuous Performance Test.

Authors:  Ashley J Porter; Katharine Pillidge; S Clare Stanford; Jared W Young
Journal:  Behav Brain Res       Date:  2015-11-11       Impact factor: 3.332

9.  The NK1R-/- mouse phenotype suggests that small body size, with a sex- and diet-dependent excess in body mass and fat, are physical biomarkers for a human endophenotype with vulnerability to attention deficit hyperactivity disorder.

Authors:  Katharine Pillidge; David J Heal; S Clare Stanford
Journal:  J Psychopharmacol       Date:  2016-07-26       Impact factor: 4.153

10.  Perseveration by NK1R-/- ('knockout') mice is blunted by doses of methylphenidate that affect neither other aspects of their cognitive performance nor the behaviour of wild-type mice in the 5-Choice Continuous Performance Test.

Authors:  Katharine Pillidge; Ashley J Porter; Jared W Young; S Clare Stanford
Journal:  J Psychopharmacol       Date:  2016-04-19       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.